Intervention

GTAEXS617

ClinicalTrials.gov intervention label

Clinical trials1

Recruiting1

Common conditions6

Lead sponsors shown1

Clinical trials

1 shown

Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsNCT05985655 · 2023-07-06

RECRUITING

Common conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)1 Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma1 Non-small Cell Lung Cancer (NSCLC)1 Pancreatic Adenocarcinoma1 Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)1 Triple Negative Breast Cancer (TNBC)1

Leading sponsors

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.1

Trial status mix

RECRUITING1

Phase mix

PHASE11

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.